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Abstract
Pancreatic ductal adenocarcinoma (PDAC) develops a pronounced stromal response reflecting an 
aberrant wound-healing process. This stromal reaction features trans-differentiation of tissue-
resident pancreatic stellate cells (PSCs) into activated cancer-associated fibroblasts (CAFs), a 
process induced by PDAC cells but of unclear significance for PDAC progression. Here we show 
that PSCs undergo a dramatic lipid metabolic shift during differentiation in the context of 
pancreatic tumorigenesis, including remodeling of the intracellular lipidome and secretion of 
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abundant lipids in the activated, fibroblastic state. Specifically, stroma-derived 
lysophosphatidylcholines support PDAC cell synthesis of phosphatidylcholines, key components 
of cell membranes, and also facilitate production of the potent wound-healing mediator 
lysophosphatidic acid (LPA) by the extracellular enzyme autotaxin, which is overexpressed in 
PDAC. The autotaxin-LPA axis promotes PDAC cell proliferation, migration and AKT activation, 
and genetic or pharmacologic autotaxin inhibition suppresses PDAC growth in vivo. Our work 
demonstrates how PDAC cells exploit the local production of wound healing mediators to 
stimulate their own growth and migration.
Keywords
lipid metabolism; tumor microenvironment; pancreatic cancer
Introduction
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer that, despite a low 
incidence, is projected to be the second highest contributor to cancer deaths by 2030 (1). 
PDAC progression typically features a dramatic desmoplastic reaction, including fibroblasts, 
immune cells and a dense extracellular matrix (2). The profound matrix deposition in the 
PDAC microenvironment physically impedes the vasculature and blocks delivery of 
intravenously injected molecules or of chemotherapeutic agents (3–5), raising the possibility 
that serum nutrients are also limited in this context. Consistent with this possibility, our 
previous metabolomic analysis of surgically resected human PDAC demonstrated that these 
tumors are nutrient-poor (6), leaving in question how PDAC cells maintain proliferative 
capacity within this nutrient-restricted microenvironment. PDAC cells were previously 
shown to scavenge extracellular protein and lipid to support proliferation (7–9). Under the 
hypovascular conditions of the PDAC microenvironment, we reasoned that PDAC cells may 
stimulate paracrine metabolite transfer from neighboring non-malignant cells to support 
their metabolism and growth, analogous to a recently described axis in metastatic melanoma 
(10).
The PDAC desmoplastic reaction is established by a prominent population of cancer-
associated fibroblasts (CAFs). This CAF population derives in part from tissue-resident 
pancreatic stellate cells (PSCs), which differentiate to a CAF phenotype upon activating 
signals from the neoplastic compartment during pancreatic tumorigenesis (11, 12). In 
healthy pancreatic tissue, PSCs are in a quiescent state, characterized by a limited secretome 
and cytoplasmic lipid droplets (13). Malignant cells signal in a paracrine manner to induce 
PSC activation to a CAF phenotype, and this is associated with loss of characteristic lipid 
droplets. Though this lipid droplet loss during stellate cell activation has long been 
appreciated, in depth, lipidome-wide investigations of intracellular remodeling and potential 
associated roles in the PDAC microenvironment have not yet been addressed. We aimed to 
understand the significance of this stromal lipid remodeling during PDAC progression, and 
to address the possibility that stroma-derived lipids support PDAC metabolism and growth. 
In the present study, we describe a novel role for PSC-derived CAFs as a source of specific, 
growth-permissive lipids in the PDAC microenvironment.
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Results
Mining of previously published RNA-seq data revealed that PSCs undergo significant 
transcriptional alterations in genes involved in lipid metabolism (14), including a broad 
downregulation of genes implicated in lipid storage (Supplementary Fig. 1A), coincident 
with acquisition of an activated, fibroblastic phenotype (Supplementary Fig. 1B). This 
includes reduced expression of the fatty acid carrier FABP4 and the lipid droplet coat 
proteins PLIN1&2 (Fig. 1A), as well as a depletion of the lipid droplet-resident triglycerides 
(Supplementary Fig. 1C). PSCs drastically reduce their capacity to store neutral lipids upon 
activation, as a near complete depletion of lipid droplets in activated PSCs was directly 
confirmed by imaging (Fig. 1B). Loss of lipid droplets during PSC activation required 
autophagy rather than neutral lipases (Supplementary Fig. 1D), consistent with previous 
findings in other contexts (15, 16). To more broadly analyze lipid metabolic changes, we 
performed intracellular lipidomics and found that PSCs undergo extensive lipidomic 
remodeling during activation, beyond loss of neutral lipids. Significant changes included a 
sharp rise in intracellular levels of lysophospholipids, particularly lysophosphatidylcholines 
(LPCs) (Fig. 1C and Supplementary Table 1). Ras-transformed cells were previously shown 
to take up extracellular lipids to support fatty acid scavenging and proliferative capacity, and 
of all lipids measured, this precise lipid class—LPCs—was the preferred scavenging 
substrate (9). Serum lipids were probed in this prior study, but we reasoned that PSC-derived 
CAFs may serve as a cellular source for these lipids in the PDAC microenvironment, which 
would align with the metabolite and protein secretory phenotype that these cells adopt. We 
thus asked whether activated PSCs secrete lysophospholipids and other lipid species as a 
potential fuel source for PDAC cells. Conditioned media (CM) from primary, activated 
mouse PSCs was analyzed by LC-MS, which revealed the presence of 230 unique secreted 
lipids including various (lyso)phospholipids, fatty acids, sphingolipids, and neutral lipids 
(Fig. 1D and Supplementary Table 1). Similar lipid secretomes were observed for 
permanently activated, immortalized mouse PSCs (lmPSCs) and immortalized human 
PDAC-derived CAFs (0082T) (Fig. 1E, Supplementary Fig. 1E and Supplementary Table 1) 
with respect to lysophospholipid species of interest and their levels, though some differences 
were noted. Differentiating primary PSCs into either iCAFs or myCAFs as previously 
described (12), yielded similar levels of LPC production (Supplementary Fig. 1F, G). To 
determine whether secreted lipids act in a paracrine manner to promote the growth of PDAC 
cells, we incubated mouse or human PDAC cells with CM from immortalized mouse PSCs 
or from primary CAFs. Consistent with earlier results, stromal cell CM elicited a 
concentration-dependent increase in PDAC cell proliferation (6, 17, 18) (Supplementary Fig. 
1H). This effect was specific to stromal cells, as PDAC CM failed to induce growth 
(Supplementary Fig. 1I). Notably, PSC CM or the CM lipid fraction alone normalized PDAC 
cell growth in fatty acid-limiting conditions, characterized by low serum lipid availability 
and fatty acid desaturation inhibition to model conditions in which PDAC cells can’t make 
all the lipids needed for proliferation (Supplementary Fig. 1J, K), strongly suggesting that 
stroma-derived lipids can support PDAC cell metabolism and growth.
To conclusively demonstrate a paracrine lipid flux from PSCs to PDAC cells, and to 
determine their metabolic fate, we performed a qualitative stable isotope tracing experiment 
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by incubating PSCs with 13C-labeled palmitate and oleate to label secreted lipids (Fig. 2A 
and Supplementary Fig. 2A). Lipidomic analysis showed significant accumulation of 13C-
labeled, stroma-derived fatty acids in PDAC cells (Fig. 2B), both in the phospholipid and 
triglyceride pools. This demonstrates that PSC-derived lipids are taken up by PDAC cells 
and channeled to various lipid pools, including phospholipids for membrane synthesis and 
growth. We next investigated specific lipid classes which may support PDAC growth and 
focused on LPCs, as they are avidly consumed by tumor cells (9), and because they are 
abundantly secreted by PSCs (Fig. 2C and Supplementary Fig. 2A). While PSCs release 
LPCs, PDAC cells do not, consistent with PDAC cell avidity for these lipids. Tracing 
experiments demonstrated that PSCs can produce LPCs from glucose and glutamine; 
however, incorporation of glucose- and glutamine-derived carbons into LPCs was 
suppressed in the presence of free fatty acids, suggesting that fatty acids are readily used for 
LPC synthesis when available (Supplementary Fig. 2B). To investigate the fate of LPCs 
upon uptake by PDAC cells, LPC 17:1 was used as a tracer, which resulted in significant 
17:1 incorporation into phosphatidylcholine species which comprise cell membranes (PC 
16:0/17:1 and PC 18:1/17:1), supporting the notion that LPCs are used by PDAC cells for 
membrane synthesis (Supplementary Fig. 2C). To determine whether activated PSCs or 
CAFs serve as the principal cellular source of LPCs in the PDAC tumor microenvironment, 
we isolated CAFs, leukocytes, or remaining cell types (PDAC cells, endothelial cells, other 
minor cell populations) by FACS, subjected these 3 populations to brief ex vivo culture, 
harvested supernatant, and analyzed LPC levels. LC-MS revealed that CAFs are the major 
producers of LPCs on a per-cell basis within the PDAC microenvironment (Fig. 2D and 
Supplementary Fig. 2D). The abundance of PDAC CAFs suggests that they are a significant 
source of these lysophospholipids in vivo, though we note that they are likely not the 
exclusive source. In addition to uptake, LPCs can be hydrolyzed in the extracellular space by 
the secreted enzyme autotaxin to give rise to lysophosphatidic acid (LPA) (Fig. 2E). LPAs 
function as potent extracellular proliferation- and migration-inducing signals with 
established roles in cancer (19), and we noticed both LPA and autotaxin in CM of cultured 
PSCs (Fig. 1D, E; Fig. 2F). PDAC cells also released autotaxin into their CM, and autotaxin 
secretion by PDAC cells was markedly increased in a paracrine manner by PSCs (Fig. 2G), 
and this induction was similar by PSCs differentiated into either iCAFs or myCAFs 
(Supplementary Fig. 2E). While the lipid fraction of PSC CM was not sufficient to induce 
autotaxin, boiled CM was (Supplementary Fig. 2F), raising the possibility that a metabolite 
or small peptide is responsible for paracrine regulation of autotaxin. Autotaxin inhibition 
with HA130 led to a drastic reduction in CM LPA levels (Supplementary Fig. 2G). Western 
blot results agreed with autotaxin activity assays (Supplementary Fig. 2H). Thus, lipids 
secreted by PSCs are directly used by PDAC cells to support membrane synthesis and act as 
substrates for the production of signaling lipids, in part through autotaxin-mediated 
hydrolysis of stroma-derived LPC.
While LPA levels in PSC CM were in the nM range, this is likely under-representative of 
actual LPA producing capacity in the tumor microenvironment, in part due the limited 
autotaxin production in homotypic PSC cultures (Fig. 2G). In addition, as the kd for LPAR1 
is ~10 nM (20), we considered that even low LPA concentrations might have potent 
biological effects. We therefore continued with determining the effect of LPAs on PDAC 
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cells. LPA receptors LPAR1 and 2 were found to be consistently expressed in PDAC cells 
(Supplementary Fig. 3A), while other LPARs were not detected. LPA-LPAR engagement 
has been shown to activate mitogenic signaling, including the PI3-kinase/AKT pathway 
(19), and PSC CM led to potent activation of AKT in PDAC cells (Fig. 3A and 
Supplementary Fig 3B). Notably, engagement of the AKT pathway by PSC CM has also 
been reported by others (21), although the underlying molecular mechanism remains ill-
defined. We found here that paracrine AKT induction was largely abolished when inhibiting 
autotaxin (Fig. 3A and Supplementary Fig. 3B) while this effect was rescued with addition 
of LPA, suggesting a central role for the stroma-derived LPC-autotaxin-LPA axis in 
paracrine regulation of AKT signaling. Similar effects were observed for the mitogenic 
MAPK pathway (Supplementary Fig. 3C).
Exogenous LPC or LPA was sufficient to induce proliferation, even in the absence of 
stromal growth factors (Fig. 3B and Supplementary Fig. 3D), implicating the stroma-derived 
LPC-autotaxin-LPA axis in PDAC cell proliferation. Consistent with this, paracrine 
induction of PDAC cell proliferation was abolished upon autotaxin inhibition (Fig. 3C, 
Supplementary Fig. 3E, 3F), an effect rescued by LPA, while autotaxin overexpression 
augmented stroma-inducible proliferation. In addition, proliferation induced by the extracted 
lipid fraction of PSC CM was also significantly reduced upon autotaxin inhibition (Fig. 3D). 
To further probe the significance of this axis in growth-permissive tumor-stroma crosstalk, 
PDAC cells and PSCs were directly co-cultured (Fig. 3E). Direct co-culture of PDAC cells 
with two separate PSC lines increased PDAC cell proliferation by nearly two-fold compared 
to mono-culture (Supplementary Fig. 3G). Strikingly, ablating LPA production with the 
autotaxin inhibitor HA130 was sufficient to cause a near 50% drop in this induced 
proliferation. This indicates that stromal LPA signaling is maintained in co-culture, and 
highlights the important role of this pathway in the proliferation-inducing effects of PSCs 
(Fig. 3F).
In addition to proliferation, LPAs can promote migration (19). Accordingly, PSC CM 
promoted migration of PDAC cells, whereas CM from PDAC cells did not (Fig. 3G and 
Supplementary Fig. 3H, I). The stromal LPA axis was the primary contributor to this effect, 
as HA130 or LPAR inhibitor Ki16425 blocked this effect (Fig. 3H and Supplementary Fig. 
3J). Autophagy-dependent alanine secretion by PSCs was recently shown to support PDAC 
cell mitochondrial metabolism (17). Autophagy inhibition in PSCs did not impair paracrine 
induction of PDAC cell migration (Supplementary Fig. 4A, 4B), and exogenous alanine did 
not stimulate PDAC cell migration or proliferation under our experimental conditions in 
these cells (Supplementary Fig. 4C, 4D), highlighting distinct functions of stroma-derived 
alanine and the lysophospholipids under present investigation. Collectively, these data show 
that stromal LPA potently induces proliferation and migration of PDAC cells.
We next established the occurrence and importance of this mechanism in vivo. We noted that 
autotaxin expression was limited to low expression in ducts in healthy pancreas, but highly 
abundant in mouse and human pancreatic tumors (Fig. 4A, 4B and Supplementary Fig. 5A). 
Interestingly, most autotaxin appeared to be on the outside of the PDAC cells rather than the 
stromal cells, and this may constitute a mechanism for generating high LPA levels in the 
vicinity of PDAC cell LPARs (Supplementary Fig. 5B). Consistently, we have found that, 
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while both cell types can produce autotaxin in homotypic cell cultures, PDAC cells produce 
more autotaxin than stromal cells in vivo (Supplementary Fig. 5C). Together with the results 
in Fig. 2G supporting stroma-inducible autotaxin expression by PDAC cells, these results 
suggest that LPA measurements in PSC or CAF CM are likely artificially low. We performed 
subcutaneous co-transplantation assays in immune-compromised mice with both PDAC cells 
and PSCs and found that PSCs increased both tumor growth (Supplementary Fig. 5D) and, 
remarkably, intratumoral LPA levels (Fig. 4C and Supplementary Table 2). To further assess 
PSCs as the source of autotaxin substrate in the PDAC microenvironment, we performed 
subcutaneous transplantation of PDAC cells and PSCs in immune-competent hosts. KPC-
derived PDAC cells were previously shown to recruit a robust innate and adaptive immune 
response in syngeneic hosts in the subcutaneous setting (22, 23), allowing us to address the 
role of pancreas-resident PSCs in complex tumor microenvironments. Autotaxin inhibition 
with the bioavailable inhibitor ONO-8430506 (24) suppressed PDAC growth to a greater 
extent in the presence of PSCs (Fig. 4D); together with Fig. 2D, these results implicate PSCs 
as a key source of autotaxin substrate in vivo. We next assessed the significance of the LPC-
autotaxin-LPA axis for PDAC growth by orthotopically injecting the pancreata of immune-
competent mice with PDAC cells, which generates a spontaneous stromal response. We then 
administered autotaxin inhibitor or vehicle control and monitored tumor growth. Autotaxin 
inhibition reduced tumor growth by ~2-fold following orthotopic injection of two different 
mouse PDAC cell lines (Fig. 4E and Supplementary Fig. 5E), and significantly reduced 
proliferation (Supplementary Fig. 5F, 5G) and AKT phosphorylation (Fig. 4F) while 
significantly increasing apoptosis (Supplementary Fig. 5H). To further assess the role of 
autotaxin in PDAC growth, 2 CRISPR-mediated Enpp2 (the gene encoding autotaxin) 
knockdown lines were generated (Supplementary Fig. 5I). Genetic disruption of Enpp2 in 
PDAC cells significantly reduced stroma-inducible proliferation in vitro (Supplementary 
Fig. 5J), and though these Enpp2 knockdown lines show proliferation defects of 36% (A11) 
or 59% (A18) under standard culture conditions in vitro, transplantation of these cells into 
pancreata of immune-competent hosts showed severely compromised tumor growth (Fig. 
4G). Importantly, proliferation was rescued with addition of autotaxin (Supplementary Fig. 
5K). These PDAC cell-restricted genetic inhibition results highlight the importance of local 
autotaxin function and LPA production for pancreatic tumor growth. Together, these results 
support a role for stromal lysophospholipid secretion in PDAC progression.
Discussion
Here we show that PSCs undergo a dramatic lipid metabolic shift during differentiation in 
the context of pancreatic tumorigenesis, including remodeling of the intracellular lipidome. 
Particularly interesting in the context of this study is the observation that intracellular LPCs 
are strongly elevated upon activation, and PSC-derived CAFs secrete abundant LPCs in the 
activated, fibroblastic state. Lipid release by PSCs promotes multiple hallmarks of 
aggressive PDAC progression, including PDAC cell proliferation and migration. Our work 
demonstrates that PSCs contribute to PDAC progression not only through the release of 
growth factors and alanine (11, 17, 25), but also specific lipid species. These lipids act as a 
source for uptake and biomass production and as precursors for signaling lipids, particularly 
LPA (Fig. 4H). The origin of intratumoral LPA in PDAC has thus far remained unclear, but it 
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was presumed to come directly from the circulation or to be made locally from circulating 
LPC. While these are likely sources, poorly perfused tumors, such as PDAC (3–6), may 
experience limited exposure to this signaling mediator via these routes. Instead, we find that 
the fibroblast-like PSCs profusely release the LPA precursor LPC, which is metabolized in 
the direct vicinity of the PDAC cells, and our results highlight the importance of this local 
LPC generation and hydrolysis as an important source of LPA (Fig. 4C, D, G). Moreover, in 
a tumor setting, PDAC cells appear to actively co-opt this signaling axis by activating 
neighboring PSCs, leading to lipidomic remodeling and coincident with LPC release, and by 
expressing both autotaxin and LPA receptors. LPA production by autotaxin may also 
contribute to the metabolic symbiosis between tumor and stroma, and an improved 
understanding of lipid uptake mechanisms will be helpful in parsing out the relative 
contributions of lipid uptake versus signaling in paracrine regulation of tumor growth by 
stromal lipid cues. Our model fits the paradigm that PDAC tumors deregulate and exploit 
normal wound healing processes for their benefit.
Previous studies employing genetic or pharmacologic means to ablate CAFs during 
pancreatic tumorigenesis revealed that PDAC that evolves in a CAF-deficient 
microenvironment is highly aggressive and more lethal than CAF-replete controls (26–28). 
Together with reports of tumor-supportive functions for PDAC CAFs, these papers suggest 
that CAFs act to suppress tumor growth, by creating a hypovascular and nutrient-poor 
microenvironment which is challenging for proliferation; but at the same time support tumor 
growth by secreting factors that enable PDAC cells to proliferate and survive in this nutrient-
poor, wound-like context. While stromal ablation therapy for PDAC remains controversial, 
our results suggest potential therapeutic opportunity in maintaining the stromal reaction, 
while identifying and targeting the specific pathways that enable growth under the nutrient-
deprived conditions of an intact tumor microenvironment.
Methods
Cell culture
Cell lines were from ATCC with the following exceptions: hPSC-T cells were kindly 
provided by R. F. Hwang and have been previously described (18). The 0082T cell line was 
derived from a primary CAF sample 0082, provided by Dr. Andrew Lowy (University of 
California San Diego) and prepared from human PDAC surgical specimens by the outgrowth 
method (29, 30). The cells were confirmed to lack KRAS exon 2 mutations and were 
immortalized with SV40 large T antigen (pLenti-SV40-T, Applied Biological Materials Inc.) 
at a MOI of 2. Primary CAF lines CAF 4414, CAF 4586, and CAF 4442 were initiated from 
disaggregated primary PDAC tumor tissue and isolated from epithelial cells by differential 
trypsinization. Immunohistochemistry and RNA-seq were used to confirm minimal 
expression of cytokeratin and abundant expression of αSMA in both CAF lines. Wild-type 
KRAS codon 12 sequence was confirmed for both CAF lines and mutant KRAS-G12 was 
confirmed in both parent tumors. Primary CAF lines were generated in accordance with 
protocols approved by the Institutional Review Boards of the University of California San 
Diego and Oregon Health & Science University. FC1199 (provided by Dr. David Tuveson) 
and 4662 (provided by Dr. Robert Vonderheide) PDAC cell lines were derived from primary 
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tumors in KPC mice. The p53 2.1.1 PDAC cell line was described previously (31). Mouse 
primary PSC isolation and immortalization was performed as described below. All cell lines 
were routinely passaged in Dulbecco’s Modified Eagle Medium (DMEM, Thermo Fisher 
Scientific) containing 10% Fetal Bovine Serum (FBS, HyClone), 25 mM glucose and 2 mM 
glutamine for no more than 25–30 passages, while primary CAFs were used for a maximum 
of 10 passages, and cells were routinely tested for mycoplasma at least monthly (MycoAlert 
Detection Kit, Lonza; latest test before submission January 28, 2019). Cell line 
authentication was not performed.
Pancreatic stellate cell isolation and immortalization
Primary PSCs were isolated from mouse pancreata as previously described (14). Briefly, 
healthy pancreata were harvested from eight-week-old male C57BL/6J mice. Tissues were 
minced with scissors and digested with 0.02% Pronase (Roche), 0.05% Collagenase P 
(Roche), and 0.1% DNase (Roche) in Gey’s balanced salt solution (GBSS; Sigma Aldrich) 
at 37°C for 20 min. After dissociation, tissue was triturated until large pieces were no longer 
visible, and the resulting cell suspension was filtered through a 100 μm nylon mesh. Cells 
were then washed with GBSS, pelleted, and resuspended in 9.5 mL GBSS containing 0.3% 
bovine serum albumin (BSA) and 8 mL 28.7% Nycodenz solution (Sigma Aldrich). The cell 
suspension was layered beneath GBSS containing 0.3% BSA, and centrifuged at 1400 × g 
for 20 min at 4°C. Stellate cells were harvested from the interface of the Nycodenz solution 
at the bottom and the aqueous solution at the top. Isolated PSCs were washed with GBSS 
and resuspended in DMEM containing 10% characterized FBS (HyClone) and antibiotics 
(100 U/mL penicillin and 100 μg/mL streptomycin, Invitrogen). Cells were maintained at 
37°C in a standard tissue culture incubator. After reaching 80% confluence, cells were 
trypsinized (0.25% Trypsin-EDTA, Invitrogen) and passaged. ImPSC1 and ImPSC2 cell 
lines were obtained by immortalizing primary PSCs with the pRetro.Super.shARF retroviral 
plasmid (kindly provided by the Karen Vousden lab) and then selected with blasticidin at a 
concentration of 4 μg/mL.
Lipid extraction and LC-MS analysis
For cellular lipids, at time of collection, primary PSCs were washed twice with ice-cold PBS 
(1 ml), cold (−20°C) PBS/MeOH (1:1) (0.75 ml) added to the dish, the cells scraped and 
transferred to a microfuge tube, and incubated at −20°C for 20 min. A mix of the following 
internal standards (Avanti Polar Lipids) was added to the final indicated concentrations, 
prior to cell scraping: FA(19:0) at 6 μM, TG(19:0/19:0/19:0) at 80 nM, CE(19:0) at 3 μM, 
PC(17:0/14:1) at 112 nM, PE(17:0/14:1) at 112 nM, LPC(17:1) at 4 μM. Cold (−20°C) 
chloroform (0.5 ml) was added, and the samples vortexed for 1 min and centrifuged for 10 
min at 18,000 × g. The lower chloroform phase was transferred to glass vials using a 
Hamilton syringe and dried under nitrogen gas. Dried samples were reconstituted in CHCl3/
MeOH (1:1) at 1 mL per 1.5 × 106 cells.
For medium apolar lipids, 0.5 ml samples were extracted by adding an equal volume of 
methanol containing 0.2 M HCl, adding same internal standards as above and then mixing 
with an equal volume of cold (−20°C) chloroform. Samples were vortexed for 1 min and 
centrifuged for 10 min at 18,000 × g. The lower chloroform phase was transferred to glass 
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vials using a Hamilton syringe and dried under nitrogen gas. Dried samples were 
reconstituted in 100 μL CHCl3/MeOH (1:1). For specific accurate quantitation of CM 
lysophosphatidylcholines (LPCs), extraction was performed as for apolar lipids, but only the 
internal standard LPC(17:1) at a final concentration of 4 μM was added, and the samples 
were reconstituted in 1 mL of methanol. For medium polar lipids, 1 mL of butanol was 
added to 750 μL of CM from PSCs containing the internal standards LPC(17:1) at 4 μM, 
FA(19:0) at 6 μM, LPA(17:0) at 10 nM. Samples were vortexed for 10 min and centrifuged 
at 20,000 × g for 5 min. The top butanol layer was transferred to glass vials and the 
extraction repeated once. The pooled extracts were dried under nitrogen gas and 
reconstituted in 100 μL of methanol.
For tumor tissue LPA analysis, tissue samples were extracted as described earlier (32) but 
with minor modifications. Briefly, 30–50 mg of the tissue sample was lysed in 0.5 mL of 
citrate phosphate buffer (15 mM citrate, 20 mM Na2HPO4, pH 4) containing the internal 
standards LPC(17:1) at 4 μM, FA(19:0) at 6 μM, LPA(17:0) at 10 nM, using a Precellys 
evolution tissue homogeniser (Bertin instruments). Following this, 1 mL of butanol was 
added to the lysate, vortexed for 10 min and centrifuged at high speed for 10 min to recover 
the butanol layer. This extraction was repeated twice and the extracts pooled and dried under 
nitrogen gas. The dried extracts were reconstituted in 100 μL of methanol.
Apolar lipids in reconstituted samples from both cells and medium were analysed using a Q 
Exactive Orbitrap mass spectrometer coupled to a Dionex UltiMate 3000 LC system 
(Thermo Scientific). The LC parameters were as follows: 5 μL of sample was injected onto a 
1.7 μm particle 100 × 2.1 mm ID Waters Acquity CSH C18 column (Waters) which was kept 
at 50°C. A gradient of (A) water/acetonitrile (40:60, v/v) with 10 mM ammonium formate 
and (B) acetonitrile/2-propanol (10:90, v/v) with 10 mM ammonium formate at a flow rate 
of 0.3 mL/min was used. The gradient ran from 0% to 40% B over 6 min, then from 40% to 
100% B in the next 24 min, followed by 100% B for 4 min, and then returned to 0% B in 2 
min where it was kept for 4 min (40 min total). The electrospray and mass spec settings were 
as follows: spray voltage 3 kV (positive mode), capillary temperature 300°C, sheath gas flow 
50 (arbitrary units), auxiliary gas flow 7 (arbitrary units) and sweep gas flow 5 (arbitrary 
units). The resolution was set to 70,000, automatic gain control to 1 × 106 with the 
maximum injection time of 200 ms and the scan range of 300–900 m/z. The peak areas for 
the different lipid species were extracted and normalised to their respective internal 
standards.
Polar lipid and LPC (for accurate quantification) extracts reconstituted in methanol were 
analysed using the same LC-MS system and settings as above, but with the following 
differences: Lipids were separated with the solvent gradient system containing (A) water and 
0.05 % NH4OH and (B) methanol and 0.05% NH4OH at the flow rate 300 μL/min. The 
separation of lipids started with isocratic elution for 2 min and 50% B followed by a linear 
gradient from 50% to 70% B over the next 10 min, and 70% to 100% B over the next 8 min. 
Thereafter, column was eluted with 100% B for 4 min and returned to initial conditions and 
equilibrated for 6 min. The peak areas for the different lipid species was extracted and 
normalised to their respective internal standards. For both apolar and polar lipid analyses, 
data was analysed with MAVEN and LipidSearch.
Auciello et al. Page 9
Cancer Discov. Author manuscript; available in PMC 2019 November 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
For targeted LPA analysis in both CM and tissues, a Vanquish UHPLC system coupled to 
TSQ Altis Triple Quadrupole mass spectrometer (Thermo) was used. 5 μL of the sample was 
loaded on a 1.7 μm particle 100 × 2.1mm ID Waters Acquity CSH C18 column. The oven 
temperature 50°C and the mobile phase consisted of (A) water and 0.05 % NH4OH and (B) 
methanol and 0.05% NH4OH. The gradient elution program was as follows: 0–1 min 
isocratic 55% B, 1–14 min 55–85% B, 14–20 min 85–100% B, 20–22 min 100% B, 22–26 
min 55% B. The total run time was 26 min and the flow rate was 250 μL/min. H-ESI 
parameters were set as follows: 2.5 kV negative mode of capillary voltage, sheath gas 50 
arbitrary units, auxiliary gas 10 arbitrary units, ion transfer tube temperature 300°C and 
vaporizer temperature 250°C. LPAs were analysed in selected reaction monitoring mode and 
30 V collision energy. SRM transitions for LPA molecules were as follows: LPA(16:0) 
409.236→152.995, 255.233; LPA(17:0) 423.252→152.995, 269.248; LPA(18:0) 
437.267→152.995, 283.264; LPA(18:1) 435.251→152.995, 281.248; LPA(18:2) 
433.236→152.995, 279.233; LPA(20:4) 457.236→152.995, 303.233. For each LPA 
molecule two product ions were used: 152.995 m/z was used for quantification, the second 
ion was used as fatty acid qualifier ion. The peak area for the different LPA species was 
extracted manually using Thermo Xcalibur 4.0 software and normalized to the peak area of 
the internal standard.
Paracrine tracing
PSCs were cultured in DMEM containing 10% FBS until 80% confluency was reached. 
Medium was then changed to DMEM with 0.5% FFAF-BSA and 100 μM of [U13C]-
palmitate and 100 μM of [U13C]-oleate (Sigma). After 24 h, medium was changed to 
DMEM containing 0.5% FFAF-BSA only and cells were left to conditioning the medium for 
48 h. Medium was then harvested and concentrated as above, diluted in DMEM containing 
0.5% FFAF-BSA to a final concentration of 4 mg/ml and provided to 60% confluent KPC 
cells. After 48 h, lipids were extracted from KPC cells and analysed as above. Data is 
presented as the percentage of the summed labelled isotopologues relative to all 
isotopologues in the respective lipids.
Ex vivo LPC release assay
Male C57Bl/6J mice at 8 weeks of age received orthotopic transplants of 5 × 103 FC1199 
cells. On day 24 post-transplantation, tumors were removed and digested for 1h in DMEM 
containing 1mg/ml collagenase IV, 0.1% soybean trypsin inhibitor, 50U/ml DNase I, 
0.125mg/ml dispase at 37°C. Tumor digests were pelleted at 300 × g for 5min, then further 
digested in 0.25% Trypsin-EDTA for 10min at 37°C. Digests were washed with cold 
DMEM containing 10% FBS and filtered through a 100μm strainer. The cell suspension was 
pelleted as above, washed with DMEM plus 10% FBS, then lysed in ACK lysis buffer 
(Thermo Fisher Scientific) at room temperature for 3min. Cells were washed in FACS buffer 
(PBS plus 2% FBS), pelleted, and resuspended in FACS buffer at 107 cells/ml. Anti-mouse 
CD16/CD32 (Fc block, BD #553142) was added at 1:20; after a 2-minute incubation, 
antibodies against CD45 (anti-CD45-FITC, BD #553080; 1:200) and Podoplanin (biotin 
anti-Podoplanin, BioLegend #127404; 1:200) were added and incubated on ice for 30min. 
Cells were washed with FACS buffer, pelleted, and resuspended in FACS buffer containing 
APC-streptavidin (BD #554067, 1:1000). After a 30min incubation on ice, cells were 
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pelleted and resuspended in FACS buffer. FITC-positive, APC-positive, and double-negative 
cell populations were identified by FACS on a BD FACSAria Fusion and sorted into FACS 
buffer. After tumors had been entirely sorted, live cells were counted, and 2 × 105 cells per 
population were seeded into 6-well plates in 2ml DMEM containing 0.5% FAF-BSA. After 
12h, culture supernatants were harvested, spun down to pellet debris, and snap-frozen for 
LPC measurement by LC-MS as described above.
Generation of Enpp2 (autotaxin) knockdown cell lines
The pSpCas9(BB)-2A-Puro(PX459) v2.0 plasmid (Addgene #62988) was used to clone 
guide sequences targeting Enpp2 per supplier’s protocol; sgRNA #1: 
CTTCCCTAATCTGTATACGC, sgRNA #2: TGGCCAGCGTATACAGATTA. The p53 2.1.1 
PDAC cell line was transfected with control plasmid or plasmid containing either of the 
sgEnpp2 sequences and subject to selection with 2μg/ml puromycin for 4 days. Single-cell 
clones were expanded and screened for autotaxin expression by Western blot. We note that 
complete knockouts were not identified in any of 4 PDAC cell lines or with any of 4 
sgRNAs tested. Degree of knockdown is demonstrated in Supplementary Data Fig. 5I.
In vivo experiments
The Institutional Animal Care and Use Committees of OHSU and the Beatson Institute 
approved all animal studies and procedures. For xenografts, 1 × 105 KPC T832043 were 
injected alone or co-injected with 5 × 105 ImPSC2 in the flanks of CD-1 nude female mice 
(Charles Rivers). Tumor dimensions were manually taken tri-weekly and tumor volume was 
calculated with the formula (width2 × length)/2. For orthotopic transplantations, male 
C57BL/6J mice at 8–10 weeks of age were anesthetized with ketamine and xylazine, and 
pancreata were injected with 5 × 103 FC1199 cells (provided by Dr. David Tuveson) or 1 × 
105 4662 cells (provided by Dr. Robert Vonderheide), both derived from primary PDAC in 
KPC mice of pure C57BL/6J background. Beginning 14 days after transplantation, pancreata 
were imaged by high-resolution ultrasound using the Vevo 770 imaging system; mice were 
enrolled in the study when tumors reached 3–6 mm in diameter, and pre-treatment tumor 
sizes were recorded. Mice were treated twice daily by oral gavage with 30 mg/kg 
ONO-8430506 dissolved in 7.5 mM NaOH, or vehicle control. After 10 days of treatment, 
post-treatment tumor measurements were performed on the Vevo 770, and mice were 
euthanized and tissues harvested for analysis. The control and Enpp2 knockdown cell lines 
in the p53 2.1.1 background were orthotopically transplanted as above but into 8-week-old 
male FVB/n mice (5 × 103 cells per mouse); tumors were imaged by high-resolution 
ultrasound on days 11 and 21 post-transplantation. For the subcutaneous transplants in 
immune-competent hosts (Fig. 4d), 8-week-old male C57Bl/6J mice were injected with 1 × 
105 FC1199 cells with or without 5 × 105 ImPSC1 cells into the left flank. Recipients were 
treated with vehicle or ONO-8430506 twice daily as described above, starting on day 1 post-
injection. Tumor volumes were measured using digital calipers, and all mice were 
euthanized when the fasting-progressing group (PDAC + PSC, vehicle) had to be sacrificed 
due to tumor volume per OHSU IACUC standards (day 21).
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Statistical analysis
All statistical analysis was performed using GraphPad PRISM software. Student’s t test was 
used to compare two groups to each other. One-way ANOVA was performed when multiple 
conditions were compared for one variable. Two-way ANOVA was used when multiple 
groups were compared for more than one variable. Tukey’s post hoc tests were used after 
both ANOVA’s analysis to perform multiple group comparison. Analysis with a P value < 
0.05 were considered significant.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Statement of significance
Our work highlights an unanticipated role for PSCs in producing the oncogenic LPA 
signaling lipid and demonstrates how PDAC tumor cells co-opt the release of wound 
healing mediators by neighboring PSCs to promote their own proliferation and migration.
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Figure 1: PSC activation leads to drastic lipid remodeling and profound lipid secretion
A, mRNA levels of Fabp4, Plin1 and Plin2 by real time PCR in pre-activated and activated 
murine primary PSCs. Expression normalized to housekeeping gene 36b4. Error bars 
represent s.d., n = 3 technical replicates from individually prepared samples from individual 
wells. B, Representative image of BODIPY staining (green) of lipid droplets in pre-activated 
(left panel) and activated primary murine PSCs (right panel). Nuclei were stained with DAPI 
(blue). C, Volcano plot showing changes in intracellular lipid levels upon activation of 
primary PSCs, as assessed by LC-MS. Data are from n = 2 individual wells per condition 
(pre-activated vs activated) with the primary cells obtained from a total of 9 mice, and are 
representative of multiple experiments. Significance determined by p value ≤0.05. D-E, 
Number of unique lipids identified for the indicated lipid classes in the medium conditioned 
by (D) primary PSCs, and (E) immortalized murine PSCs (ImPSC1) and immortalized 
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human PDAC CAFs (0082T). Lipids identified in each of n = 3 individual wells of a 
representative experiment. Abbreviatons: Cer, ceramide; CerG, glucosylceramide; CerP, 
phosphatidylceramide; ChE, cholesterol-ester; cPA, cyclic phosphatidic acid; DG, 
diglyceride; FA, (free) fatty acid; LPA, lysophosphatidic acid; (L)PC, 
(lyso)phosphatidylcholine; (L)PE, (lyso)phosphatidylethanolamine; LPG, 
(lyso)phosphatidylglycerol; LPI, lysophosphatidylinositol LPS, (lyso)phosphatidylserine; 
n.s., non-significant; SM, sphingomyelin; TG, triglyceride.
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Figure 2: PSC secreted lipids are a source for biomass and signaling molecules
A, Schematic of paracrine tracing experimental procedure: ImPSC1 were cultured with 
[U13C]-palmitate and [U13C]-oleate for 24h. Labeled fatty acids were removed and new 
medium was left to condition for 48h. Labelled CM was provided to KPC T832043 for 48h 
before intracellular lipid analysis by LC-MS lipidomics. B, Percentage labeling of 
intracellular lipids of KPC T832043 cells exposed to labeled CM from ImPSC1. Labelled 
isotopologs for each lipid were summed and expressed as a percentage of all isotopologs of 
that respective lipid. Error bars indicate s.d. of n = 3 individual wells of a representative 
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labeling experiment. C, Lysophosphatidylcholine (LPC) levels in CM from murine (left 
panel) and human (right panel) PSCs and PDAC cells after 48h of conditioning, by LC-MS. 
Error bars represent s.e.m. of independent experiments (n =2), each conducted in triplicate 
wells. D, LPC levels in culture supernatants from the indicated cell populations (CD45+ 
leukocytes; Pdpn+ CAFs; and double-negative PDAC cells, endothelial cells, and other 
minor cell populations), isolated from murine PDAC by FACS and cultured ex vivo for 12h. 
Error bars represent s.e.m. of n = 3 tumors. E, Potential routes by which lysophosphatidic 
acid (LPA) can accumulate in PSC CM. F, Representative Western blot of autotaxin released 
into the CM by both PSCs (ImPSC1, hPSC-T) and PDAC (MIA PaCa2, PANC-1, KPC 
iRFP, KPC T832043) cells. KPC cells overexpressing autotaxin (KPC high ATX served as a 
positive control. G, Representative Western blot of autotaxin released into the CM by 
FC1199 PDAC cells, ImPSC, or FC1199 cultured with either CM (or SF DMEM control) for 
24h. Significance determined by one-way ANOVA; ***, p ≤ 0.0001.
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Figure 3: Stromal LPA induces AKT signaling, proliferation and migration of PDAC cells
A, Representative Western blot of phospho-AKT (Ser473) and total AKT in 8988T cells 
cultured in CAF 4414 CM in the presence or absence of HA130(ATXi) (10μM) and LPA 
18:1 (10μM) for 5min. Serum-free DMEM (SF DMEM) and 10% FBS-DMEM were used as 
negative and positive controls, respectively. B, Proliferation after 72 hours (details in 
Methods) of 8988T cells in the presence of 10μM LPC 18:1 or LPA 18:1, with or without 
10μM HA130 (ATXi). DMEM with 10% FBS was a positive control. Error bars indicate 
s.e.m. of independent experiments (n=3), each performed in triplicate wells. C, Proliferation 
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after 72 hours of 8988T cells in CAF 4414 CM, with or without 10μM HA130 (ATXi) or 
10μM LPA 18:1. Error bars indicate s.e.m. of independent experiments (n=3), each 
performed in triplicate wells. D, Proliferation after 72 hours of KPC-iRFP cells in ImPSC1 
CM or the CM lipid fraction (CML), in the presence or absence of 10μM HA130 (ATXi). 
Error bars represent s.e.m. of independent experiments (n=3), each performed in triplicate 
wells. E, Schematic of experimental procedure: KPC cells expressing iRFP were seeded 
with ImPSCs in a ratio of 1:5. Cell fluorescence was monitored after 48h. F, KPC cells 
expressing iRFP co-cultured with ImPSC1 in presence or absence of HA130 (ATXi) 
(10μM). Proliferation of PDAC cells only was assessed by fluorescence. Error bars indicate 
s.e.m. of independent experiments (n = 3), each performed in triplicate wells. G, Velocity of 
AsPC-1 cells in a scratch wound assay (see Material and Methods) when incubated with CM 
from PSCs (0082T and hPSC-T) and PDAC (MIA PaCa-2 and PANC-1) cells. Error bars 
represent s.d. of 90 individual cells over triplicate wells from an experiment that was 
representative of 3 independent experiments. H, Scratch wound assay where KPC T832043 
were incubated with CM from ImPSC1 in presence or absence of LPA receptor inhibitor 
Ki16425 (10μM) or autotaxin inhibitor HA130 (ATXi) (10μM). Velocity of cells was 
evaluated. Error bars represent s.d. of 90 individual cells in triplicate wells representative of 
3 independent experiments. Significance determined by one-way ANOVA; * p ≤ 0.05,** p ≤ 
0.001, ***, p ≤ 0.0001.
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Figure 4: Autotaxin is highly expressed in tumors and its inhibition retards tumor growth
A, Representative tissue microarray (TMA) image from a set of 78 pancreatic cancer 
patients, with benign adjacent tissue (left panel) and PDAC tissue (right panel) stained for 
autotaxin. B, Quantification of autotaxin positive ductal cells in the benign adjacent tissue 
and in PDAC tissue from a set of 78 pancreatic cancer patients. C, Concentration of LPA in 
xenografts from CD-1 nude mice injected with either KPC T832043 or a combination of 
KPC T832043 and ImPSC2 in a ratio of 1:5. 5 mice per condition were used and horizontal 
lines indicate means and the whiskers minimum and maximum values. D, Tumor volumes 
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from FC1199 cells upon subcutaneous transplantation into C57Bl/6J hosts, with or without 
ImPSC1 in a 1:5 ratio, treated with vehicle or ONO-8430506. Error bars represent s.e.m. of 
10 mice per condition. E, Percent tumor growth assessed in mice orthotopically implanted 
with 4662 KPC cells, which leads to a spontaneous stromal response, and treated either with 
vehicle or with ONO-8430506. Treatment started 14 days after implantation and lasted 10 
days, 10 mice were used and horizontal lines indicate means, the boxes interquartile ranges, 
and the whiskers minimum and maximum values. F, Quantification of pAkt IHC in mice 
orthotopically injected with 4662 KPC cells and treated with vehicle or ONO-8430506. 6 
mice per condition were used and horizontal lines indicate means and the whiskers 
minimum and maximum values G, Tumor size from time of orthotopic transplantation in 
FVB/n hosts (vector, n=6; sgEnpp2 lines, n=8 per line) Error bars represent s.e.m. H, 
Activated PSCs abundantly release lipids, including LPCs, into the microenvironment. These 
lipids support PDAC membrane lipid synthesis. Additionally, LPCs can be converted to LPA 
by extracellular autotaxin. Through the LPA receptors located on PDAC cell membranes, 
LPAs modulate signaling of PDAC cells and consequently, their proliferation and migration. 
Significance was determined by paired t-test (B), multiple t-test (C), unpaired t-test (F, G), 
or two-way ANOVA (D, H); *p ≤ 0.05, ** p ≤ 0.005, *** p ≤ 0.001.
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